Modern science offers a novel strategy to target the most challenging infections fueled by biofilms. Learn more about our important work to combat these infections and reduce antibiotic resistance.Our Science An innovative, strategically focused management team with gene therapy, global drug development, and new venture development expertise.Meet The Team In the News David Richards Appointed CEO of Clarametyx BiosciencesJanuary 5, 2021 Newly Published Insights in Biofilm Illustrate the Powerful Mechanisms of an Antibody Biofilm Eradication Therapy ApproachDecember 1, 2020 Clarametyx Biosciences Awarded Up to $14.2 Million From Carb-x to Accelerate Novel Immune-enabling Technology to Combat Persistent Bacterial InfectionsNovember 18, 2020 Data Published in Ebiomedicine Validates Novel Scientific Approach that Disarms Bacterial Defenses to Treat or Prevent Life-threatening InfectionsJuly 7, 2020
